Summary
Breast cancer (BC) is the most diagnosed cancer worldwide, and despite treatment availability, the disease remains challenging to treat, causing substantial adverse side effects and fatalities globally. The lack of efficacy and inaccessibility of standard care supports this demand for better treatments. This is demonstrated by resection surgery and current (neo)adjuvant therapies such as chemotherapy exhibiting inadequacies resulting in 30% of BC patients having metastases. These percentages are even higher in low human index regions due to inaccessibility, cost and growing populations. Adoptive cell therapy (ACT), such as CAR-T, is a category of emerging immunotherapies expected to impact oncology by transferring engineered immune cells into a patient to eliminate cancer cells. However, these treatments are currently ineffective in BC and costly.
END-BC will complement research into B cells to produce an ACT that improves treatment efficacy against breast cancer while reducing side effects and costs from effective therapy. Our research developed novel biomaterial to overcome significant obstacles to successfully enhance B cell functions against cancer using a low-cost method. In END-BC, we will research the commercial and technical feasibility of tailoring the B cell ACT with biomaterials to determine its potential to treat BC.
END-BC will complement research into B cells to produce an ACT that improves treatment efficacy against breast cancer while reducing side effects and costs from effective therapy. Our research developed novel biomaterial to overcome significant obstacles to successfully enhance B cell functions against cancer using a low-cost method. In END-BC, we will research the commercial and technical feasibility of tailoring the B cell ACT with biomaterials to determine its potential to treat BC.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101138825 |
| Start date: | 01-01-2024 |
| End date: | 30-06-2025 |
| Total budget - Public funding: | - 150 000,00 Euro |
Cordis data
Original description
Breast cancer (BC) is the most diagnosed cancer worldwide, and despite treatment availability, the disease remains challenging to treat, causing substantial adverse side effects and fatalities globally. The lack of efficacy and inaccessibility of standard care supports this demand for better treatments. This is demonstrated by resection surgery and current (neo)adjuvant therapies such as chemotherapy exhibiting inadequacies resulting in 30% of BC patients having metastases. These percentages are even higher in low human index regions due to inaccessibility, cost and growing populations. Adoptive cell therapy (ACT), such as CAR-T, is a category of emerging immunotherapies expected to impact oncology by transferring engineered immune cells into a patient to eliminate cancer cells. However, these treatments are currently ineffective in BC and costly.END-BC will complement research into B cells to produce an ACT that improves treatment efficacy against breast cancer while reducing side effects and costs from effective therapy. Our research developed novel biomaterial to overcome significant obstacles to successfully enhance B cell functions against cancer using a low-cost method. In END-BC, we will research the commercial and technical feasibility of tailoring the B cell ACT with biomaterials to determine its potential to treat BC.
Status
SIGNEDCall topic
ERC-2023-POCUpdate Date
12-03-2024
Images
No images available.
Geographical location(s)
Search
